home > ict > winter 2020 > harmonising requirements in the eu


Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.


News and Press Releases

Prometheus’ PRA023 holds significant advantage over all therapies for Crohn’s Disease, says GlobalData

At the European Crohn´s and Colitis Organisation (ECCO), Prometheus Bioscience presented results from its Phase 2a APOLLO-CD clinical trial of PRA023 in Crohn’s Disease (CD). The presentation highlighted the efficacy and safety of PRA023, an anti-TL1A asset, in the small sample size (N=50) of CD patients. The area of particular interest from this presentation was the reported findings of Prometheus’ proprietary companion diagnostic test (CDx) being evaluated alongside PRA023. If this asset is shown to be effective and advance to the market, the use of the CDx with PRA023 gives the treatment and Prometheus a significant advantage over all CD therapies currently in development and on the market, according to GlobalData, a leading data and analytics company.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement